Omeros Corp. Stock
Omeros Corp. Stock
Omeros Corp. dominated the market today, gaining €0.35 (3.570%).
With 21 Buy predictions and not a single Sell prediction Omeros Corp. is an absolute favorite of our community.
With a target price of 30 € there is potential for a 195.57% increase which would mean more than doubling the current price of 10.15 € for Omeros Corp..
Our community identified positive and negative aspects for Omeros Corp. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Omeros Corp. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.
Pros and Cons of Omeros Corp. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omeros Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omeros Corp. | 3.570% | 21.122% | 17.749% | 204.805% | -24.815% | 158.533% | -16.564% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
Omeros (OMER) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for OMER provided by MarketBeat
Omeros (OMER) had its price target lowered by HC Wainwright from $40.00 to $33.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OMER provided by MarketBeat
Omeros (OMER) had its "buy" rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
News
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
Choosing between Heartflow (NASDAQ:HTFL) and Omeros (NASDAQ:OMER) in 2026 requires balancing the rapid revenue growth of an AI diagnostic platform against the high-stakes commercial launch of a new
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique
Omeros Q1 Earnings Call Highlights
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA
